(69 days)
Not Found
The provided text does not contain any K/DEN numbers. Therefore, I cannot identify and list them.
No
The summary describes a standard in vitro diagnostic assay for measuring iron binding capacity and does not mention any AI or ML components.
No.
The device is described as an "in vitro diagnostic device intended to measure iron binding capacity," which is used in the diagnosis and treatment of anemias, but it does not directly treat or provide therapy to a patient.
Yes
The "Intended Use / Indications for Use" section explicitly states, "The ADVIA IMS Unsaturated Iron Binding Capacity (UIBC) assay is an in vitro diagnostic device..."
No
The device is an in vitro diagnostic device intended to measure iron binding capacity in human serum, which implies it is a physical device that performs laboratory analysis, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "The ADVIA IMS Unsaturated Iron Binding Capacity (UIBC) assay is an in vitro diagnostic device intended to measure iron binding capacity in human serum..."
N/A
Intended Use / Indications for Use
The ADVIA IMS Unsaturated Iron Binding Capacity (UIBC) assay is an in vitro diagnostic device intended to measure iron binding capacity in human serum and dlagmostly are new inding capacity are used in the diagnosis and treatment of anemias.
Product codes
JMO
Device Description
This in vitro diagnostic procedure is intended to measure iron-binding capacity in human Such measurement is used in the diagnosis and serum.on the Bayer ADVIA® IMS™. treatment of anemia.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Imprecision
ADVIA IMS
Level (ug/dL): 48.0, Total CV(%): 10.6
Level (ug/dL): 157, Total CV(%): 3.4
Level (ug/dL): 537, Total CV(%): 1.0
CHEM 1
Level (ug/dL): 141, Total CV(%): 5.3
Level (ug/dL): 306, Total CV(%): 6.3
Level (ug/dL): 559, Total CV(%): 4.5
Correlation (Y=ADVIA IMS, X=comparison system)
Specimen type: Serum, Comparison System (X): CHEM 1, N: 58, Regression Equation: Y=0.96X-8.76, Syx (ug/dL): 7.86, R: 0.997, Sample Range (ug/dL): 41.5 - 538.0
Specimen type: Plasma(y), Serum(x), Comparison System (X): ADVIA IMS, N: 50, Regression Equation: Y=0.99X-1.70, Syx (ug/dL): 3.04, R: 0.999, Sample Range (ug/dL): 114.1 - 438.9
Interfering Substances
Interfering Substance: Bilirubin (unconjugated), Interfering Sub. Conc. (mg/dL): 12.5, UIBC Conc (ug/dL): 212.7, Effect (% change): -10
Interfering Substance: Bilirubin (conjugated), Interfering Sub. Conc. (mg/dL): 12.5, UIBC Conc (ug/dL): 208.2, Effect (% change): -5
Interfering Substance: Lipids (Triglycerides), Interfering Sub. Conc. (mg/dL): 250, UIBC Conc (ug/dL): 211.7, Effect (% change): -69
Analytical Range
Serum/Plasma: 30 to 560 ug/dL
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Technicon CHEM
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1415 Iron-binding capacity test system.
(a)
Identification. An iron-binding capacity test system is a device intended to measure iron-binding capacity in serum. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
OCT - 1 2001
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS Unsaturated Iron Binding Capacity (UIBC) method for ADVIA® IMS™
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92.
The assigned 510(k) number is: HQ10340
1. Intended Use
This in vitro diagnostic procedure is intended to measure iron-binding capacity in human Such measurement is used in the diagnosis and serum.on the Bayer ADVIA® IMS™. treatment of anemia.
2. Predicate Device
| The Research As and Children Company of Children Comments of Children Comments of
| Product Name | agent Part # Calibrator Part # | |
|---|---|---|
| Technicon CHEM | ||
| t | T01-1869-53 T03-1291-62 |
3. Device / Method
| Product Name | REF | Calibrator Part # |
|---|---|---|
| Bayer ADVIA IMS | 06254177 | T03-1291-62 |
A. Imprecision
| ADVIA IMS | CHEM 1 | |||
|---|---|---|---|---|
| Level | ||||
| (ug/dL) | Total | |||
| CV(%) | Level | |||
| (ug/dL) | Total | |||
| CV(%) | ||||
| 48.0 | 10.6 | 141 | 5.3 | |
| 157 | 3.4 | 306 | 6.3 | |
| 537 | 1.0 | 559 | 4.5 |
Correlation (Y=ADVIA IMS, X=comparison system)
| Specimen type | Comparison System (X) | N | Regression Equation | Syx (ug/dL) | R | Sample Range (ug/dL) |
|---|---|---|---|---|---|---|
| Serum | CHEM 1 | 58 | $Y=0.96X-8.76$ | 7.86 | 0.997 | 41.5 - 538.0 |
| Plasma(y), Serum(x) | ADVIA IMS | 50 | $Y=0.99X-1.70$ | 3.04 | 0.999 | 114.1 - 438.9 |
Interfering Substances
| Interfering
Substance | Interfering Sub.
Conc. (mg/dL) | UIBC Conc
(ug/dL) | Effect
(% change) |
|--------------------------|-----------------------------------|----------------------|----------------------|
| Bilirubin (unconjugated) | 12.5 | 212.7 | -10 |
| Bilirubin (conjugated) | 12.5 | 208.2 | -5 |
| Lipids (Triglycerides) | 250 | 211.7 | -69 |
Analytical Range
Serum/Plasma: 30 to 560 ug/dL
1
Alexis
7/20/01
Freerick Clerie
Manager Regulatory Affairs Bayer Corporation
511 Benedict Avenue Tarrytown, New York 10591-5097
Date
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of a human figure in profile, with three overlapping shapes representing the head, body, and legs.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT - 1 2001
Kenneth T. Edds, Ph.D. Manager Regulatory Affairs Bayer Corporation 511 Benedict Avenue Tarrytown, NY 10591-5097
Re: K012340
Trade/Device Name: ADVIA IMS® Unsaturated Iron binding Capacity (UIBC) Regulation Number: 21 CFR 862.1415 Regulation Name: Iron-binding capacity test system Regulatory Class: Class I Product Code: JMO Dated: July 19, 2001 Received: July 24, 2001
Dear Dr. Edds:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for association to May 28, 1976, the enactment date of the Medical Device Amendments, or to econimer to prox co ria) 2011-03-2014 accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket I his letter will anow you to ocen marketing , o walence of your device to a legally marketed notification. The PDA inding of successification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (2) CFF Part 801 and 1 II you desire specific acrico roll "see are contact the Office of Compliance at additionally 809.10 for in vius diagliostions on the promotion and advertising of your device, (201) 594-4388. Additionally, for questions of (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general entitled, "Misoranding by reference to precise to precised from the Division of Small information on your responsionales and Consumer Assistance at its toll-free number (800) 638-2041 or Manufacturers International and October "http://www.fda.gov/cdrb/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
510(k) Number (if known): KO12340
Device Name: ADVIA IMS® Unsaturated Iron binding Capacity (UIBC)
Indication For Use:
The ADVIA IMS Unsaturated Iron Binding Capacity (UIBC) assay is an in vitro diagnostic device intended to measure iron binding capacity in human serum and dlagmostly are new inding capacity are used in the diagnosis and treatment of anemias.
(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | ||
|---|---|---|
| Prescription Use | OR | Over-The-Counter Use ______ |
| (Per 21 CFR 801.109) |
(Division Sign-Off)
Kevin Alexander Johnston Optional Formal 1-2-96
Division of Clinical Laboratory Devices
| 510(k) Number | K012340 |
|---|---|
| --------------- | --------- |